- Purple Biotech Ltd. announced on **October 29, 2025**, the achievement of a **manufacturing milestone for IM1240**, a tri-specific antibody from its CAPTN-3 platform, by establishing a **commercially viable yield** and validating the platform's scalability.  **[1614744_0001213900-25-103254_ea0262930-6k_purple.htm:0]** **[1614744_0001213900-25-103254_ea026293001e99-1_purple.htm:0]** 
- **IM1240**, the first CAPTN-3 tri-specific antibody, is advancing toward first-in-human clinical trials, with an **Investigational New Drug (IND) submission planned for 2026**.  **[1614744_0001213900-25-103254_ea026293001e99-1_purple.htm:0]** 
- The company developed a **high-efficiency manufacturing and purification process** for tri-specific antibodies, designed to deliver a differentiated T cell engager with a capped, cleavable polypeptide to help prevent off-tumor immune activation.  **[1614744_0001213900-25-103254_ea026293001e99-1_purple.htm:0]**

Purple Biotech achieves manufacturing milestone for IM1240

- Purple Biotech Ltd. (PPBT) received a Nasdaq notification on **October 16, 2025**, for non-compliance with the **$1.00 minimum bid price** rule, as its American Depositary Shares (ADSs) traded below this threshold for **30 consecutive days**.  **[1614744_0001213900-25-100353_ea026181801ex99-1_purple.htm:0]** 
- The company has **180 calendar days**, until **April 14, 2026**, to regain compliance by achieving a closing bid price of **$1.00 or more for ten consecutive business days**.  **[1614744_0001213900-25-100353_ea026181801ex99-1_purple.htm:0]** 
- This notification has **no immediate effect** on the company's Nasdaq listing or the trading of its ADSs.  **[1614744_0001213900-25-100353_ea026181801ex99-1_purple.htm:0]** 
- Purple Biotech intends to monitor its ADS bid price and may consider options to cure the deficiency, including potentially **changing the ratio between its ADSs and ordinary shares**.  **[1614744_0001213900-25-100353_ea026181801ex99-1_purple.htm:0]**

Purple Biotech receives Nasdaq minimum bid price notification

- Purple Biotech Ltd. entered into an **At The Market Offering Agreement** with H.C. Wainwright & Co., LLC on **September 19, 2025**, to offer and sell American Depositary Shares (ADSs) with an aggregate offering price of up to **$2,300,000**.  **[1614744_0001213900-25-089661_ea0258001-6k_purple.htm:0]** **[1614744_0001213900-25-089661_ea025800101ex1-1_purple.htm:0]** **[1614744_0001213900-25-089661_ea025800101ex5-2_purple.htm:0]** 
- Each ADS under the new agreement represents **200** ordinary shares, and H.C. Wainwright & Co., LLC will receive a **3.0% placement fee** on the gross sales price.  **[1614744_0001213900-25-089661_ea0258001-6k_purple.htm:0]** **[1614744_0001213900-25-089661_ea025800101ex1-1_purple.htm:0]** **[1614744_0001213900-25-089661_ea025800101ex5-2_purple.htm:0]** **[1614744_0001213900-25-089661_ea025800101ex1-1_purple.htm:3]** 
- Effective **September 18, 2025**, the company **terminated its Open Market Sale Agreement** with Jefferies LLC.  **[1614744_0001213900-25-089661_ea0258001-6k_purple.htm:0]** 
- Under the terminated Jefferies ATM Program, Purple Biotech sold **983,317 ADSs** for aggregate gross proceeds of **$7,729,691**, at an average price of **$7.86 per ADS**.  **[1614744_0001213900-25-089661_ea0258001-6k_purple.htm:0]**

Purple Biotech Enters New At The Market Offering Agreement

- Purple Biotech reported a **cash balance of $10.5 million as of September 10, 2025**, providing a **cash runway into the first half of 2027**.  **[1614744_0001213900-25-087788_ea025747001ex99-1_purple.htm:3]**  
- The company is progressing two first-in-class drugs in Phase 2: **CM24**, an aCEACAM1 antibody with **positive randomized Phase 2a results** for pancreatic cancer, and **NT219**, an IRS1/2 degrader and STAT3 blocker, which initiated a Phase 2 study in **June 2025** for recurrent/metastatic Head & Neck Cancer.  **[1614744_0001213900-25-087788_ea025747001ex99-1_purple.htm:3]**    
- Development continues for **CAPTN-3**, a next-generation tri-specific antibody platform, with first-in-human trials anticipated in **2026**.  **[1614744_0001213900-25-087788_ea025747001ex99-1_purple.htm:3]**

PURPLE BIOTECH (PPBT)